Levofloxacin Based Sequential and Triple Therapy Compared with Standart Plus Probiotic Combination for Helicobacter Pylori Eradication        
Yazarlar (8)
Kamil Özdil
Umraniye Education And Research Hospital, Türkiye
Turan Çalhan
Umraniye Education And Research Hospital, Türkiye
Prof. Dr. Abdurahman ŞAHİN Fırat Üniversitesi, Türkiye
Ebubekir Şenateş
Dicle Üniversitesi, Türkiye
Resul Kahraman
Umraniye Education And Research Hospital, Türkiye
Bilgehan Yüzbaşıoğlu
Umraniye Education And Research Hospital, Türkiye
Hakan Demirdağ
Umraniye Education And Research Hospital, Türkiye
Hüseyin Demirsoy
Sakarya Education And Research Hospital, Türkiye
Makale Türü Özgün Makale
Makale Alt Türü SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale
Dergi Adı Hepato Gastroenterology
Dergi ISSN 0172-6390
Dergi Tarandığı Indeksler SCI-Expanded
Dergi Grubu Q4
Makale Dili İngilizce
Basım Tarihi 07-2011
Cilt No 58
Sayı 109
Sayfalar 1148 / 1152
DOI Numarası 10.5754/hge11075
Makale Linki https://www.hepato-gastroenterology.org/?p=1998
Özet
Background/Aims: Development of resistance to standard therapy for Helicobacter pylori (H. pylori) eradication is rapid. The aim of this study is to compare the efficacy of alternative treatment modalities for H. pylori. Compared treatments were standard triple treatment plus probiotic, sequential therapy with levofloxacin, and a 14-day regimen of PPI (proton pump inhibitor) and levofloxacin/amoxicillin combination. Methodology: Overall 285 patients were enrolled in the study and allocated into three groups. Group I (n=98) received lansoprazole, clarithromycin, amoxicillin and saccharomyces boulardii (probiotic) and group II (n=95) received esomeprazole, levofloxacin and amoxicillin for 14 days. Finally, group III (n=92) received esomeprazole and amoxicillin for five days, followed by esomeprazole, levofloxacin and metronidazole for seven days. Testing for H. pylori infection posttreatment was done using a stool antigen test five weeks after the completion of therapy. Results: Patients in all three groups were treatment-naive. Response to treatment (Per Protocol/ITT analysis) was 77.1/72.4% in Group I, 89.1/86.3% in Group II, and 95.5% in Group III. Response to treatment was significantly higher in Groups II and III compared to Group I (p=0.03 and p<0.001, respectively). There was no difference between Groups II and III in terms of response to treatment (p=0.1). Conclusions: Levofloxacin-based sequential therapy and levofloxacin based triple therapy were significantly superior to standard triple therapy plus probiotic. © H.G.E. Update Medical Publishing S.A.
Anahtar Kelimeler
H. pylori eradication therapy | Helicobacter pylori | Levofloxacin | Sequential